Department of Bioscience and Biotechnology, Banasthali University, Banasthali, RJ 304 022, India.
Cancer Biology Laboratory, Department of Biochemistry and Bioinformatics, GIS, GITAM, Visakhapatnam, Andhra Pradesh 530045, India.
Drug Discov Today. 2024 Jul;29(7):104053. doi: 10.1016/j.drudis.2024.104053. Epub 2024 Jun 6.
Pancreatic cancer (PC), a disease with high heterogeneity and a dense stromal microenvironment, presents significant challenges and a bleak prognosis. Recent breakthroughs have illuminated the crucial interplay among RAS, epidermal growth factor receptor (EGFR), and hedgehog pathways in PC progression. Small molecular inhibitors have emerged as a potential solution with their advantages of oral administration and the ability to target intracellular and extracellular sites effectively. However, despite the US FDA approving over 100 small-molecule targeted antitumor drugs, challenges such as low response rates and drug resistance persist. This review delves into the possibility of using small molecules to treat persistent or spreading PC, highlighting the challenges and the urgent need for a diverse selection of inhibitors to develop more effective treatment strategies.
胰腺癌（PC）是一种具有高度异质性和密集基质微环境的疾病，存在着巨大的挑战和严峻的预后。最近的突破揭示了 RAS、表皮生长因子受体（EGFR）和 hedgehog 途径在 PC 进展中的关键相互作用。小分子抑制剂因其口服给药的优势和有效靶向细胞内和细胞外部位的能力而成为一种潜在的解决方案。然而，尽管美国食品和药物管理局批准了 100 多种小分子靶向抗肿瘤药物，但仍存在反应率低和耐药性等挑战。这篇综述探讨了使用小分子治疗持续性或转移性 PC 的可能性，强调了面临的挑战以及迫切需要多样化的抑制剂选择，以开发更有效的治疗策略。
